• 1
    Alderson, M.R., Tough, T.W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K.A., Goodwin, R.G., Smith, C.A., Ramsdell, F., Lynch, D.H. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. Journal of Experimental Medicine, 181, 71 77.
  • 2
    Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W., Yuan, J. (1996) Human ICE/CED-3 protease nomenclature. (Letter). Cell, 87, 171.
  • 3
    Badley, A.D., McElhinny, J.A., Leibson, P.J., Lynch, D.H., Alderson, M.R., Paya, C.V. (1996) Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Journal of Virology, 70, 199 206.
  • 4
    Berenson, R.J., Bensinger, W.I., Kalamasz, D. (1986) Positive selection of viable cell populations using avidin-biotin immunoadsorption. Journal of Immunological Methods, 91, 11 19.
  • 5
    Bogdanovic, A.D., Jankovic, &G.M., Colovic, M.D., Trpinac, D.P., Bumbasirevic, V.Z. (1996) Apoptosis in bone marrow of myelodysplastic syndrome patients. (Letter). Blood, 87, 3064.
  • 6
    Cascino, I., Papoff, G., De Maria, R., Testi, R., Ruberti, G. (1996) Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. Journal of Immunology, 156, 13 17.
  • 7
    Dexter, T.M., Allen, T.D., Lajtha, L.G. (1977) Conditions controlling the proliferation of haemopoietic stem cells in vitro. Journal of Cellular Physiology, 91, 335-344.
  • 8
    Dhein, J., Walczak, H., Baumler, C., Debatin, K.M., Krammer, P.H. (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373, 438 441.
  • 9
    Ganser, A., Seipelt, G., Hoelzer, D. (1991) The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes. American Journal of Clinical Oncology, 14, (Suppl. 1), S34 S39.
  • 10
    Gersuk, G.M., Lee, J.W., Beckham, C.A., Anderson, J., Deeg, H.J. (1996) Fas (CD95) receptor and fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome (Letter). Blood, 88, 1122 1123.
  • 11
    Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079 2088.
  • 12
    Greenberg, P.L. (1992) Treatment of myelodysplastic syndromes with hemopoietic growth factors. Seminars in Oncology, 19, 106 114.
  • 13
    Greinix, H.T., Storb, R., Bartelmez, S.H. (1992) Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules. Blood, 80, 1950 1956.
  • 14
    Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363 1366.
  • 15
    Hatake, K., Tomizuka, H., Ikeda, M., Tsunoda, J., Hoshino, Y., Ohtsuki, T., Kasahara, T., Yonehara, S., Miura, Y. (1994) The presence of apoptosis in refractory anemia of myelodysplasia. Molecular Biology of Haematopoiesis(ed. by N. Abraham, R. K. Shadduck, A. S. Levine and F. Takaku), p. 127. Intercept Ltd, Andover.
  • 16
    Heyman, M.R. (1991) Recent advances in biology and treatment of myelodysplasia. Current Opinion in Oncology, 3, 44 53.
  • 17
    Hong, D.-S., Beckham, C., Huss, R., Lee, J.W., Hockenbery, D., Ledbetter, J.A., Deeg, H.J. (1995) Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand. Blood, 86, 3341 3352.
  • 18
    Iijima, N., Miyamura, K., Itou, T., Tanimoto, M., Sobue, R., Saito, H. (1997) Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood, 90, 4901 4909.
  • 19
    Kiener, P.A., Davis, P.M., Starling, G.C., Mehlin, C., Klebanoff, S.J., Ledbetter, J.A., Liles, W.C. (1997) Differential induction of apoptosis by Fas–Fas ligand interactions in human monocytes and macrophages. Journal of Experimental Medicine, 185, 1511 1516.
  • 20
    Krammer, P.H., Dhein, J., Walczak, H., Behrmann, I., Mariani, S., Matiba, B., Fath, M., Daniel, P.T., Knipping, E., Westendorp, M.O., Stricker, K., Baumler, C., Hellbardt, S., Germer, M., Peter, M.E., Debatin, K.M. (1994) The role of APO-1-mediated apoptosis in the immune system. Immunological Reviews, 142, 175 191.
  • 21
    Lee, J.W., Gersuk, G.M., Kiener, P.A., Beckham, C., Ledbetter, J.A., Deeg, H.J. (1997) HLA-DR-triggered inhibition of hematopoiesis involves Fas/Fas-ligand interactions and is prevented by c-kit ligand. Journal of Immunology, 159, 3211 3219.
  • 22
    Liles, W.C., Kiener, P.A., Ledbetter, J.A., Aruffo, A., Klebanoff, S.J. (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. Journal of Experimental Medicine, 184, 429 440.
  • 23
    Loken, M.R., Terstappen, L.W.M.M., Civin, C.I., Fackler, M.J. (1992) Flow cytometric characterization of erythroid, lymphoid and monomyeloid lineages in normal human bone marrow. Flow Cytometry in Hematology(ed. by O. D. Laerum and R. Bjerksnes), p.31. Academic Press, New York.
  • 24
    Maciejewski, J., Selleri, C., Anderson, S., Young, N.S. (1995a)Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 3183 3190.
  • 25
    Maciejewski, J.P., Selleri, C., Sato, T., Anderson, S., Young, N.S. (1995b)Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. British Journal of Haematology, 91, 245 252.
  • 26
    Maekawa, K., Imagawa, N., Nagamatsu, M., Harada, S. (1994) Molecular cloning of a novel protein-tyrosine phosphatase containing a membrane-binding domain and GLGF repeats. FEBS Letters, 337, 200 206.
  • 27
    Mayer, R.J. & Canellos, G.P. (1996) Primary myelodysplastic syndrome and secondary preleukemic disorders. Leukemia(ed. by E. S. Henderson, T. A. Lister and M. F. Greaves), p.513. Saunders, Philadelphia.
  • 28
    Mohler, K.M., Torrance, D.S., Smith, C.A., Goodwin, R.G., Stremler, K.E., Fung, V.P., Madani, H., Widmer, M.B. (1997) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. Journal of Immunology, 151, 1548 1561.
  • 29
    Moller, N.P., Moller, K.B., Lammers, R., Kharitonenkov, A., Sures, I., Ullrich, A. (1994) Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain. Proceedings of the National Academy of Sciences of the United States of America, 91, 7477 7481.
  • 30
    Mufti, G.J. (1992) A guide to risk assessment in the primary myelodysplastic syndrome. Hematology/Oncology Clinics of North America, 6, 587 606.
  • 31
    Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., Dixit, V.M. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85, 817 827.
  • 32
    Nagata, S. (1997) Apoptosis by death factor. Cell, 88, 355 365.
  • 33
    Nagata, S. & Golstein, P. (1995) The Fas death factor. Science, 267, 1449 1456.
  • 34
    Nagler, A., MacKichan, M.L., Negrin, R.S., Donlon, T., Greenberg, P.L. (1995) Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. Leukemia, 9, 30 39.
  • 35
    Noel, P. & Solberg, L.A. (1992) Myelodysplastic syndromes: pathogenesis, diagnosis and treatment. Critical Reviews in Oncology/Hematology, 12, 193 215.
  • 36
    O'connell, J., O'sullivan, G.C., Collins, J., Shanahan, F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medicine, 184, 1075 1082.
  • 37
    Rajapaksa, R., Ginzton, N., Rott, L.S., Greenberg, P.L. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275 4287.
  • 38
    Rathmell, J.C., Cooke, M.P., Ho, W.Y., Grein, J., Townsend, S.E., Davis, M.M., Goodnow, C.C. (1995) CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature, 376, 181 184.
  • 39
    Raza, A., Gezer, S., Gregory, S.A., Venugopal, P., Kaizer, H., Dong, L.M., Span, L., Hines, C., Thomas, R., Alvi, S., Mundle, S.D., Shetty, V., Borok, R., Loew, J., Reza, S., Robin, E.L., Rifkin, S.D., Alston, D., Hernandez, B.M., Shah, R., Hsu, W.-T., Dar, S., Preisler, H.D. (1996a)Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). (Abstract). Blood, 88, 580a.
  • 40
    Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S., Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268 276.
  • 41
    Raza, A., Mundle, S., Shetty, V., Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H., Gregory, S., Preisler, H. (1996b)A paradigm shift in myelodysplastic syndromes. Leukemia, 10, 1648 1652.
  • 42
    Reems, J.A. & Torok-Storb, B. (1995) Cell cycle and functional differences between CD34+/CD38hi and CD34+/38lo human marrow cells after in vitro cytokine exposure. Blood, 85, 1480 1487.
  • 43
    Sato, T., Irie, S., Kitada, S., Reed, J.C. (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science, 268, 411 415.
  • 44
    Selleri, C., Sato, T., Del Vecchio, L., Luciano, L., Barrett, A.J., Rotoli, B., Young, N.S., Maciejewski, J.P. (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood, 89, 957 964.
  • 45
    Shetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J., Gregory, S., Rifkin, S., Gezer, S., Parcharidou, A., Venugopal, P., Shah, R., Hernandez, B., Klein, M., Alston, D., Robin, E., Dominquez, C., Raza, A. (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Research, 20, 891 900.
  • 46
    Sievers, E.L., Lange, B.J., Buckley, J.D., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., Shults, K.E., Bernstein, I.D., Loken, M.R. (1996) Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute, 88, 1483 1488.
  • 47
    Smith, C.A., Farrah, T., Goodwin, R.G. (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76, 959 962.
  • 48
    Smith, M.A. & Smith, J.G. (1991) The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leukemia Research, 15, 597 601.
  • 49
    Srour, E.F., Brandt, J.E., Briddell, R.A., Grigsby, S., Leemhuis, T., Hoffman, R. (1993) Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood, 81, 661 669.
  • 50
    Stelzer, G.T., Shults, K.E., Loken, M.R. (1993) CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Annals of the New York Academy of Sciences, 677, 265 280.
  • 51
    Suda, T. & Nagata, S. (1994) Purification and characterization of the Fas-ligand that induces apoptosis. Journal of Experimental Medicine, 179, 873 879.
  • 52
    Suda, T., Okazaki, T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K., Nagata, S. (1995) Expression of the Fas ligand in cells of T cell lineage. Journal of Immunology, 154, 3806 3813.
  • 53
    Suda, T., Takahashi, T., Golstein, P., Nagata, S. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169 1178.
  • 54
    Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C., Eaves, C.J. (1990) Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proceedings of the National Academy of Sciences of the United States of America, 87, 3584 3588.
  • 55
    Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A.H., Nagata, S. (1996) Fas ligand in human serum. Nature Medicine, 2, 317 322.
  • 56
    Terstappen, L.W., Safford, M., Konemann, S., Loken, M.R., Zurlutter, K., Buchner, T., Hiddemann, W., Wormann, B. (1992) Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia, 6, 70 80.
  • 57
    Vignaux, F., Vivier, E., Malissen, B., Depraetere, V., Nagata, S., Golstein, P. (1995) TCR/CD3 coupling to Fas-based cytotoxicity. Journal of Experimental Medicine, 181, 781 786.
  • 58
    Watanabe-Fukunaga, R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A., Nagata, S. (1992) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. Journal of Immunology, 148, 1274 1279.
  • 59
    Yamaguchi, M., Gersuk, G., Nadler, S., Deeg, H.J. (1996) HLA-DR mediated apoptosis and inhibition of hematopoiesis involves upregulation of tumor necrosis factor alpha. (Abstract). Experimental Hematology, 24, 1100.
  • 60
    Yoshida, Y. (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia, 7, 144 146.